RecruitingNCT05740696

Registry Study for Optimal Management of Liver Failure in the Chinese Population

Registry Study for Optimal Management of Liver Failure in the Chinese Population (RESOLVE-C)


Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Enrollment

500 participants

Start Date

Jan 6, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.


Eligibility

Inclusion Criteria4

  • Patients with a diagnosis consistent with liver failure and pre-liver failure:
  • Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention;
  • Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L);
  • Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.

Exclusion Criteria1

  • An event or complication that, in the judgment of the investigator, significantly affects the assessment of clinical status.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREALF

Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks

PROCEDURESALF

The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks

PROCEDUREACLF

On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period


Locations(14)

First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Ankang Central Hospital

Ankang, China

Xiangya Hospital of Central South University

Changsha, China

Hanzhong 3201 Hospital

Hanzhong, China

Qilu Hospital of Shandong University

Jinan, China

First Hospital of Lanzhou University

Lanzhou, China

Weinan Central Hospital

Weinan, China

Air Force Medical University Tangdu Hospital

Xi'an, China

Shaanxi provincial people's hospital

Xi'an, China

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China

Xi 'an International Medical Center Hospital

Xi'an, China

Xianyang Central Hospital

Xianyang, China

The Affiliated Hospital of Yan'an University

Yanan, China

General Hospital of Ningxia Medical University

Yinchuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05740696


Related Trials